Robert J. Kinders
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Cancer Cells and Metastasis, Cancer therapeutics and mechanisms, DNA Repair Mechanisms, Cancer, Stress, Anesthesia, and Immune Response
Most-Cited Works
- → Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies(2009)328 cited
- → Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors(2015)318 cited
- → Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers(2010)256 cited
- → Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas(2011)252 cited
- → Cediranib for Metastatic Alveolar Soft Part Sarcoma(2013)218 cited
- → Compressing drug development timelines in oncology using phase '0' trials(2007)213 cited
- → A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas(2012)201 cited
- → Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors(2017)170 cited
- → Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition(2009)169 cited
- → Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity(2009)161 cited